The Medical Research Council is funding a £20m research hub in Cambridge that will use AI and advanced laboratory models to develop new medicines. The hub will be based at the Cambridge Stem Cell Institute on the Cambridge Biomedical Campus and will work with Cambridge University Hospitals NHS Foundation Trust (CUH).
Researchers will use human tissue and disease models to improve how lab-based research becomes new treatments. CUH said the hub would create "more accurate ways to study, predict and develop treatments for human diseases before they are trialled in patients" and would reduce dependence on animal research.
Human models and mini-organs
The hub will rely on lab-grown mini-organs called "organoids", stem cell systems, AI approaches, bioengineering, and clinical research. These tools are meant to capture the characteristics of individual patients, which can make drug testing more reliable before human trials begin.
Professor Matthias Zilbauer, hub co-leader and honorary consultant at CUH, said: "By capturing important characteristics of individual patients, these human models allow us to study disease more accurately and test potential treatments before they reach the clinic."
Zilbauer said the initiative could "ultimately lead to more effective, personalized therapies while reducing the time and cost of developing drugs".
Leadership and partners
The hub will be led by Zilbauer and Professor Bertie Göttgens, director of the Cambridge Stem Cell Institute and co-leader of the hub. Partners include the Wellcome Sanger Institute, the MRC Laboratory of Molecular Biology, and Royal Papworth Hospital NHS Foundation Trust.
Göttgens said: "By bringing together hospitals, research institutes and industry partners in Cambridge and across the UK, the Hub will advance the development and use of new, more accurate research tools that better reflect human biology to improve the development of new therapies."
For researchers working in drug discovery and translational science, the hub signals a concrete shift toward human-relevant models over animal testing. That direction has implications for how studies are designed, how data from organoids and stem cell systems are interpreted, and how AI is integrated into preclinical workflows. Professionals in this space may want to track the hub's methods and outputs as they emerge, since they could set a template for similar initiatives elsewhere. For those looking to build skills in this area, AI for Science & Research and AI for Research Scientists offer relevant training pathways.
Why this matters for science and research professionals
The hub's focus on organoids, stem cell systems, and AI points to a practical question for researchers: how to validate and standardize these models so regulators and clinicians trust them. The project brings together hospitals, research institutes, and industry partners specifically to address that translation gap. Scientists working in drug development should watch how the hub handles data sharing, model validation, and clinical integration - those decisions will shape best practices for AI-assisted biomedical research.
Your membership also unlocks:
